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are alive (5 with autologous recovery) with 25 thalassemia free with
a mean and median follow up time of 392 and 257 days respectively
(range 7-1,760 days) as of April 28, 2006. The median day to
hospital discharge was day 58 (range 22-137 days). An analysis
was undertaken to compare experienced centers (5 cases) with
less experienced centers, as well as compare units that were post-
thaw washed versus units that were not post-thaw washed (Table
5). These results show that when cell dose is optimal and post-thaw
wash is not used, at experienced centers, unrelated CBT may be a
promising approach for the curative therapy of thalassemia major.
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REDUCED INTENSITY CONDITIONING IN STEM CELL TRANSPLANTA-
TION FOR NON-MALIGNANT DISORDERS
Shenoy, Shalini. Washington University School of Medicine and Saint
Louis Children’s Hospital, Saint Louis, MO.
Background: Hematopoietic stem cell transplantation (HSCT)
is curative in several non-malignant disorders including hemoglo-
binopathies. It is limited by donor availability, regimen related
toxicities, graft rejection, and GVHD. HSCT is often restricted to
myeloablative regimen and matched related donors.
Study objective: To determine whether children with non-
malignant disorders achieve donor engraftment with lowered tox-
icity following reduced intensity conditioning (RIT).
Study design: Fifty-two children received related or unrelated
donor transplants after conditioning with Campath-1H, ﬂudara-
bine, and melphalan (140 or 70 mg/m2). GVHD prophylaxis in-
cluded cyclosporine or tacrolimus, short course methotrexate (3
doses), and methyl prednisone. Patients were 8 months to 20 years
old; 4 had failed previous transplants; 12 had received transfusion
therapy for 8 months to 12 years. Indications for HSCT included
hemoglobinopathy (6), bone marrow failure (7), immune dysfunc-
tion (25), metabolic disorders (13) and autoimmunity (1). Marrow/
peripheral blood (41) was 7-8/8 allele matched and cord blood (11)
was 4-5/6 antigen matched.
Results: All but 2 patients, both with hemoglobinopathy who
received the lower melphalan dose, engrafted. Myeloid (ANC0.5
109/L) and platelet (50 109/L) engraftment occurred at a median
of 13 (10-36) and 26 (12-82) days. At median follow up of 14 months
(5-52), overall and event free survival were 87% and 77%. Treatment
related mortality was 11%. Grade 2-4 acute GVHD developed in
15%; chronic GVHD in 11% between 6-9 months post transplant.
Post transplant complications were predominantly bacterial and viral
infections; all in the ﬁrst 6 months post HSCT. Hemoglobinopathy
patients tolerated conditioning without toxicity and successfully en-
grafted donor cells only with the higher dose of melphalan.
Conclusions: This RIT regimen was well tolerated and achieved
donor engraftment irrespective of stem cell source in non-malig-
nant disorder patients at high risk for graft rejection with accept-
able rates of TRM and GVHD.
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STANDARDIZATION OF CFU ASSAYS FOR CORD BLOOD (CB) PRODUCTS
Clarke, E. for the NMDP Proﬁciency Testing Committee. StemCell
Technologies Inc., Vancouver, BC, Canada.
The advantages of using CB derived cells for the treatment of
leukemia and other hematological malignancies are now well rec-
ognized. However, the selection of the most appropriate CB prod-
uct could be enhanced if functional data, e.g., a colony forming cell
(CFC) assay was available. Such data may only be of utility if
centers elect to use a standardized protocol and agree to report on
similar criteria, so in association with the NMDP, a proﬁciency
testing program was designed speciﬁcally to evaluate the challenges
and variability of CFC assessment from both fresh and frozen CB
samples. Unprocessed fresh CB cells from a designated bank were
shipped to 28 participants who were asked to perform a total
nucleated cell count (TNC) and viability assessment and transfer a
ﬁxed number of viable cells to the tube of MethoCult™ provided.
Following 14 days, participants were asked to score and report
BFU-E, CFU-GM and total CFC numbers. All centers reported
data for all variables. In the second program, 41 participants re-
ceived a vial of frozen CB cells from a designated bank and asked
to perform similar analyses. All centers reported values for TNC
and viability but only 60% of participants reported growth of
progenitors. The coefﬁcient of variation (CV) for cell assessment
from fresh CB was signiﬁcantly lower than that from frozen CB,
though the CVs for CFCs were similar.
Investigation as to the reported lack of growth at 40% of centers
is underway. There was no statistically signiﬁcant association be-
tween shipping method (cryo-shippers or dry ice) and CFC
growth, but the reported TNC numbers correlated with CFC
proliferation, suggesting transient warming of the samples or an
extended time frame between thawing, sampling and plating.
These data suggest that adherence to standardized protocols for
cell assessment and colony enumeration may facilitate global ap-
plicability of data generated at various banks.
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TRANSPLANTATION OUTCOME OF PLASMA DEPLETED CORD BLOOD
UNIT AND THE EFFECT OF POST-THAW WASHING
Chow, Robert,1,8 Nademanee, Auayporn,2 Rosenthal, Joseph,2
Karanes, Chatchada,2 Jaing, Tang-Her,3 Graham, Michael,4
Wang, Brian,5 Gjertson, David,5 Chan, Lee Lee,6 Eames, Gretchen,7
Tan, Ah Moy,9 Tan, Poh-Lin,10 Lin, Hai-Peng,11 Tan, Patrick,12
Petz, Lawrence.1,5 1StemCyte International Cord Blood Center, Arcadia,
CA, & StemCyte Taiwan National Cord Blood Center, Linko, Taiwan;
2City of Hope National Medical Center, Duarte, CA; 3Chang Gung
University & Children’s Hospital, Linko, Taiwan; 4University of Ari-
zona Medical Center, Tuscon, CA; 5UCLA Medical Center & School of
Public Health, Los Angeles, CA; 6University of Malaya Medical Center,
Kuala Lumpar, Malaysia; 7Cook Children’s Hospital, Fort Worth, TX;
8StemCyte Research Institute, Arcadia, CA; 9KK Women & Children’s
Hospital, Singapore; 10National University Hospital, Singapore; 11Sub-
ang Jaya Medical Center, Kuala Lumpar, Malaysia; 12Mount Elizabeth
Hospital, Singapore.
We studied the outcome of cord blood transplantation (CBT)
using two approaches to maximize cord blood (CB) cell dose—
depletion of plasma (PD) but not of red blood cells during CB
processing, and no post-thaw washing (NW). All 237 known PD
CB used in 215 patients up to 3/2006 were analyzed; median age 9
yo, range 0.3-59 with 33% 16 yo; median weight 30 kg, range
4.5-112 with 35% 50 kg; male 60%; median #HLA ABDR
matches 4.0; median TNC dose 5.3  107/kg; median CD34 dose
1.8  105/kg; transplant center reported median post-thaw TNC
dose of 4.4  107/kg; malignant indications 70%; transplants
outside U.S. 39%; double transplant 27%; and non-myeloablative
16%. The incidence of grade III-IV aGVHD and extensive
cGVHD was 13% and 14% respectively. Unadjusted engraftment
rate of ANC500, platelet 20,000 and 50,000 engraftment were 88
 3%, 82  4% and 76  4% respectively. The median time to
engraftment for ANC 500, platelet 20,000 and 50,000 was 22, 48,
and 63 days respectively. Relapse rate was 23  4% and TRM was
29  3%. With a median follow-up of 325 days, 1-year overall
survival and disease-free survival are 59  4% and 54  4%
respectively. Stratiﬁcation analysis showed worse engraftment and
survival outcome at CD34 cell dose below 0.7  107/kg.
There were 113 washed (W) and 95 non-washed (NW) PD
CBTs. No signiﬁcant adverse events occurred when the recom-
mended DMSO threshold of 1g per kg recipient weight was not
exceeded. TNC recovery after thawing as reported by transplant
centers is higher for NW (median 89% vs 75%).
Table 6. Mean Cell Values Obtained by CB Centers
CVs from
Fresh CB
(n  28)
CVs from
Frozen CB
(n  41)
TNC (106/mL) 6.1% 16.5%
Viability 3.2% 35.7%
Total viable cells (106/mL) 6.4% 40.9%
BFU-E 40.6% 40.4%
CFU-GM 65.0% 55.0%
Total CFC 34.4% 35.3%
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Unadjusted engraftment rates were higher and median time to
engraftment was earlier for NW than W PD CB: 91  4% and 20
days for NW vs 88  4% and 24 days for W for ANC 500 (P 
0.03), 86  6% and 44 days for NW vs 78  5% and 58 days for
W for platelet 20,000 (P  0.004), 85  6% and 57 days for NW
vs 72 6% and 75 days for W for platelet 50,000 (P 0.01). Acute
grade III-IV GvHD incidence was 12% (NW) and 13% (W), and
extensive chronic GvHD was 4% (NW) and 19% (W). Relapse
rates were 16  5% for NW and 28  5% for W (P  0.15), with
TRM for at 25  5% for NW and 34  5% for W (P  0.52).
One-year OS was 63 6% vs 49 5% (P 0.40), and 1-year DFS
was 62  6% vs 36  7% for NW and W (P  0.21), respectively.
Outcome for PD CBT compare favorably to published data of
outcomes using RBC depleted CBT and trended better with re-
spect to engraftment, TRM and survival. There appears to be no
clear beneﬁt for post-thaw washing of PD CB, and not washing
may be better than post-thaw washing of PD CB with respect to
neutrophil and platelet engraftment rate and speed to engraftment,
TRM, relapse rate, 1-year OS and DFS.
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COMPARISON OF CORD BLOOD PRODUCT THAWING METHODS ON
CELL RECOVERY AND PROGENITOR INTEGRITY
Regan, D.M.,1 Grunzinger Nelms, L.M.,1 Wofford, J.D.,1
Alonso, J.F. III,1 Creer, M.H.2 1St. Louis Cord Blood Bank @ SSM
Cardinal Glennon Children’s Hospital, St. Louis, MO; 2St. Louis Uni-
versity Health Sciences Center, St. Louis, MO.
Umbilical cord blood (UCB) products have traditionally been
thawed using a conventional washing (CW) method intended to
stabilize the cells, reduce DMSO toxicity and remove potentially
ABO-incompatible RBC stroma and plasma. Concerns with CW
include total nucleated cell (TNC) loss, bag breakage during cen-
trifugation and poor reproducibility by transplant centers unfamil-
iar with this technique. We compared CW, albumin reconstitution
without centrifugation (AR), and direct thaw (DT, no dilution or
wash) methods by assessing viability and TNC, CD34 and colony-
forming cell (CFC) recovery post-thaw. Ten cryopreserved UCB
products were thawed, split equally into three parts, processed by
CW, AR and DT methods and post-thaw tests performed at
multiple time intervals up to 48 hours. Mean TNC recovery by
CW was lower than DT (P  0.01) throughout the 48 hour
interval, however, CW and AR recoveries were not different (P 
0.05). CD34 and CFC in CW, AR and DT did not differ up to 2
hours but CFC recovery in DT progressively declined with no
CFC recovered at 32 hours. In DT, CD34 recovery declined
progressively after eight hours compared to AR and CW (P 
0.0009). Throughout the entire evaluation, CW and AR methods
performed equally well with no signiﬁcant differences observed in
viability, TNC, CD34 or CFC recovery. Subsequent to the success
of this study, AR has been used for 6 patients with no apparent
effect on engraftment compared to CW.
We conclude that removing DMSO, RBC stroma and plasma post
thaw using CW is not necessary when CB products are RBC and
plasma depleted before cryopreservation and have implemented the
practice of reconstituting units in our laboratory where environmental
conditions are controlled and the infused product characterized. Re-
constituting products is safe, easily standardized and comparable to
conventional wash in maintaining cellular and progenitor integrity
while ensuring recipient safety during infusion.
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GRAFT-VERSUS-LEUKEMIA EFFECT AFTER ALLOGENEIC TRANSPLAN-
TATION FOR ACUTE LEUKEMIA
Eapen, Mary. Center for International Blood and Marrow Transplant
Research (CIBMTR), Milwaukee, WI.
It is widely accepted that donor lymphocytes can eradicate tumor
cells that survive preparative regimens and the occurrence of
chronic graft-versus-host disease (GVHD) associated with fewer
relapses. This lower risk does not always translate into a survival
advantage, as chronic GVHD is associated with higher transplant-
related mortality (TRM).
We examined the inﬂuence of GVHD on relapse and mortality in
an era where peripheral blood grafts are increasing used for allogeneic
transplantation. We performed a retrospective analysis of 1754 recip-
ients of HLA-matched sibling donor transplants in 1996-2003 for
acute lymphoblastic (ALL) or acute myeloid (AML) leukemia. Com-
pared to patients with ALL, those with AML were older, more likely
to be in 1st clinical remission and receive a non-total body irradiation
containing regimen. All patients received non-manipulated grafts and
approximately 50% received peripheral blood grafts.
After adjusting for other signiﬁcant factors, relapse rates were sim-
ilar in those with and without acute GVHD. The inﬂuence of chronic
GVHD on relapse, TRM and overall mortality varied by type of
leukemia. Chronic GVHD was associated with lower relapse rates in
ALL (RR 0.83, P  0.013) but relapse rates were not statistically
different in AML (RR 0.96, P  0.496). Among patients with AML,
TRM was higher in those with both acute (RR 1.45, P  0.005) and
chronic (RR 1.65, P 0.003) GVHD, a trend not seen amongst those
with ALL. While overall mortality rates did not differ signiﬁcantly in
patients with and without acute GVHD, rates were signiﬁcantly lower
in patients with ALL who developed chronic GVHD (RR 0.80, P 
0.001). This survival advantage contrasts most reports and requires
conﬁrmation in a larger data set. Though GVHD rates were higher
after transplantation of peripheral blood relative to bone marrow, the
inﬂuence of GVHD on relapse and mortality did not differ by graft
type suggesting that there may be a GVHD threshold beyond which
there is no additional beneﬁt with respect to either recurrence or
survival.
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NK CELLS AND KIR MISMATCH IN CORD BLOOD TRANSPLANTATION
Miller, Jeffrey S., Brunstein, Claudio G., McKenna, David H.,
Wagner, John E. Blood and Marrow Transplant Program, University of
Minnesota, Minneapolis, MN.
We have shown that NK cell killer Ig-like receptor (KIR) interac-
tions predict better survival in recipients of adult donor unrelated
transplant. We studied KIR reconstitution from recipients at day
100 after transplant from different allogeneic cell sources. Adult
marrow unrelated donor grafts resulted in signiﬁcantly lower KIR
recovery than from UCB sources (27.31 2.06%, n 36 vs 37.99
2.54%, n  49, P  .0027), which may have clinical consequences.
We have recently found that NK cell receptor expression deﬁnes
maturation on developing NK cells and hypothesized that NK cell
alloreactivity would predict oucomes in recipients of UCBT. We
therefore assessed the effect of KIR-L MM in 243 recipients of UCB
transplanted at the University of Minnesota. KIR-L MM in the GVH
direction was found in 70 (29%) donor-recipient pairs.
Using this strategy, there was no difference in 2-year survival, or
GVHD. In contrast, relapse was less in recipients of single UCB
transplants who were KIR-L MM but for the entire group, the
incidence of TRM was higher among recipients of KIR-L MM grafts
[26% vs 13%, P  0.01] complicating detection of any possible
beneﬁt. Although we fail to support a speciﬁc search for UCB units
with a KIR-L MM, we are exploring methods to better activate NK
cells in vivo to optimize NK cell effects to decrease relapse after UCB
transplant. Based on our experience using haploidentical NK cells
from adult donors, we ﬁnd that anti-tumor activity in AML patients
corresponds with the in vivo expansion of NK cells stimulated by a
surge in endogenous IL-15 but NK cells. In an attempt to improve on
these outcomes, NK cell precursors from a third UCB unit are being
expanded in vivo after a myeloablative conditioning to test the NK cell
therapy potential of UCB in patients with poor prognosis AML.
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DIFFERENTIATION OF NAIVE CORD BLOOD T CELLS INTO CD19-SPE-
CIFIC CYTOLYTIC EFFECTORS FOR POST-TRANSPLANTATION ADOP-
TIVE IMMUNOTHERAPY
Cooper, Laurence J.N. MD Anderson Cancer Center, Houston, TX.
Disease relapse is a barrier to achieving therapeutic success after
unrelated umbilical cord blood transplantation (UCBT) for
B-lineage acute lymphoblastic leukemia (B-ALL). While adoptive
transfer of donor-derived tumor-speciﬁc T cells is a conceptually
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